Patents Examined by Dennis J Parad
-
Patent number: 11291635Abstract: Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen. These particles are useful as components in pharmaceutical compositions for immunising subjects against various diseases.Type: GrantFiled: July 6, 2011Date of Patent: April 5, 2022Assignee: GLAXOSMITHKLINE BIOLOGICAL SAInventors: Andrew Geall, Christian Mandi, Derek O'Hagan, Manmohan Singh
-
Patent number: 11083750Abstract: Provided herein are topical formulations containing copper ions and methods of treating inflammatory, microbial, and arthritic conditions in various areas of the body using such formulations. Methods of treating osteoarthritis using topical copper ion treatments are provided. Methods of treating and preventing microbial infections using copper ion treatments are further provided, including methods of preventing biofilm. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension is combined with various carriers to form the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.Type: GrantFiled: September 14, 2016Date of Patent: August 10, 2021Assignee: CDA RESEARCH GROUP, INC.Inventors: Dominic C. Abbott, ChunLim Abbott
-
Patent number: 11052109Abstract: Provided herein are topical formulations containing copper ions and methods of treating inflammatory, microbial, and arthritic conditions in various areas of the body using such formulations. Methods of treating osteoarthritis using topical copper ion treatments are provided. Methods of treating and preventing microbial infections using copper ion treatments are further provided, including methods of preventing biofilm. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension is combined with various carriers to form the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.Type: GrantFiled: September 14, 2016Date of Patent: July 6, 2021Assignee: CDA RESEARCH GROUP, INC.Inventors: Dominic C. Abbott, ChunLim Abbott
-
Patent number: 10986857Abstract: The present invention provides compositions and methods for the dietary management of nephrolithiasis and hypocitraturia through the oral administration of multiple alkali salts including sodium bicarbonate, potassium citrate and/or magnesium citrate. Also provided are kits including compositions for the dietary management of nephrolithiasis and hypocitraturia.Type: GrantFiled: August 22, 2018Date of Patent: April 27, 2021Assignee: LithoLyte CorporationInventor: Ryan Holland
-
Patent number: 10973946Abstract: The present invention relates to a haemostatic material comprising a carrier layer and a material for wound contact comprising at least one haemostat in particulate, granular, powder, flake or short fibrous form. Such a haemostatic material is useful, for example, in reducing or stopping bleeding of a physiological target site in a person or animal, and can also be used to stem bleeding during medical procedures.Type: GrantFiled: May 22, 2015Date of Patent: April 13, 2021Assignee: Medtrade Products LimitedInventors: Craig Julian Hardy, Andrew Darby, Guy Eason
-
Patent number: 10952979Abstract: Vaginal lubricants that have salts which are biomatched to salts that are naturally present in the vagina facilitate intercourse without toxic effects. Topical substances that have a low buffering capacity to promote fertility by providing lubricity while minimizing disturbance to the natural pH levels present during intercourse. A low buffering capacity reduces the extent to which a product interferes with natural pH and buffering capacity of fluids that are present during intercourse.Type: GrantFiled: November 14, 2018Date of Patent: March 23, 2021Assignee: GOOD CLEAN LOVE, INC.Inventor: Wendy Strgar
-
Patent number: 10945974Abstract: Methods of weight management for a subject are provided. Generally the methods comprising: administering an effective amount to the small intestine and/or large intestine of the subject of at least one agent that increases oxygen tension and/or redox potential and/or pH in the colon of the subject to thereby manage the weight of the subject. Also provided are compositions comprising at least one agent that increases oxygen tension and/or redox potential and/or pH, wherein the composition is formulated for delivery of an effective amount of the at least one agent to the small intestine and/or large intestine of a subject following oral ad ministration of the composition to the subject.Type: GrantFiled: May 31, 2016Date of Patent: March 16, 2021Assignee: Xeno Biosciences Inc.Inventor: Hasan Celiker
-
Patent number: 10940236Abstract: A synthetic composite material for tissue repair is disclosed which includes a first layer having an organic material and having side walls and external surface; and a second porous layer comprising an inorganic material and having side walls; wherein the first layer is in direct contact with the second layer and wherein the side walls of the first layer and the side walls of the second layer are coated with a third layer of the organic material.Type: GrantFiled: May 19, 2014Date of Patent: March 9, 2021Assignees: OSPEDALE SAN RAFFAELE S.R.L., UNIVERSITÀ DEL SALENTOInventors: Giuseppe Peretti, Gianfranco Fraschini, Alessandro Sannino, Francesca Gervaso, Francesco Scalera, Alessia Di Giancamillo, Cinzia Domeneghini, Daniela Rosa Deponti
-
Patent number: 10940159Abstract: A combination immediate/delayed release delivery system for compounds which have short half-life's, such as the antidiabetic remogliflozin etabonate, is provided which provides a dosage form that has two distinct phases of release, a formulation that promotes immediate release of the compound upon ingestion and another formulation which delays the release of the compound so that a dosing regimen of remogliflozin etabonate, once daily, may be achieved while providing effective control of plasma glucose and minimizing the nighttime exposure of this compound. The delivery system includes, but is not limited to, a combination of enteric coating of an immediate release formulation such that a delay in release is provided. Methods for forming the so-described immediate/delayed release delivery system and using such delivery system for treating diabetes are also provided.Type: GrantFiled: July 7, 2011Date of Patent: March 9, 2021Inventors: James Trinca Green, William Owen Wilkison
-
Patent number: 10933040Abstract: A process for producing a pharmaceutical lozenge formulation comprising the steps of: (a) providing a liquid composition comprising a salt of a non-steroidal anti-inflammatory drug (NSAID salt) and a solvent system, (b) providing a molten lozenge-forming composition, (c) mixing the liquid composition with the molten lozenge-forming composition, and, (d) forming the resulting mixture into lozenges each containing a therapeutically effective amount of said NSAID salt/NSAID mixture. The present application discloses the corresponding NSAID-containing lozenge compositions and their use for the manufacture of a medicament for treating sore throat.Type: GrantFiled: June 24, 2019Date of Patent: March 2, 2021Assignee: RECKITT BENCKISER HEALTHCARE (UK) LIMITEDInventors: Kirsty Sawicka, Jasmine Takhar, Paul Marshall, Michael Fanfarillo
-
Patent number: 10933009Abstract: The present invention provides compositions and methods for treating a dermatological disorder or disease.Type: GrantFiled: May 14, 2018Date of Patent: March 2, 2021Assignee: Vapogenix, Inc.Inventor: Danguole Spakevicius
-
Patent number: 10912785Abstract: A medical device for the treatment of papilloma virus (HPV) skin infections is the object of this invention, in particular for the treatment of warts and related pathologies. In particular, this invention relates to acetylsalicylic acid for use in the topical treatment, of HPV skin infections in particular benign infections and more in particular warts. Acetylsalicylic acid may be administered by plaster or patch, both in a solid state, such as a tablet, powder or granulate, and by a hydrophilic or hydrophobic gel.Type: GrantFiled: September 5, 2016Date of Patent: February 9, 2021Assignee: Poli MD S.R.L.Inventor: Elena Poli
-
Patent number: 10894024Abstract: Compounds for treating reward deficiency syndrome (RDS) behaviors and methods of use and administration of such compounds to induce dopamine homeostasis. These compounds synergistically combine two or more of (a) DP A, (b) NAC, and (c) kyotorphin (or arginine and tyrosine, the precursors of kyotorphin). These work together to enhance dopamine release by employing mechanisms tied to GABA regulation on Dorsal Raphe VGlut3 neurons via the Substania Nigra and increasing enkephalins (by increasing the release of enkepahlins and by the inhibition of enkephalinase). The resulting compound can induce dopamine homeostatis (and thus induce anti-stress states and diminish stress induced addictive behaviors). In embodiments of the present invention, the compound further includes nano-sized particles that enable the compound to be water- or powder-based even though DP A, NAC, and kyotorphin are not soluble in water.Type: GrantFiled: December 7, 2015Date of Patent: January 19, 2021Assignee: SYNAPTAMINE, INC.Inventor: Kenneth Blum
-
Patent number: 10888516Abstract: According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.Type: GrantFiled: March 27, 2020Date of Patent: January 12, 2021Assignee: TherapeuticsMD, Inc.Inventors: Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner, Thorsteinn Thorsteinsson, Janice Louise Cacace, Frederick D. Sancilio, Neda Irani
-
Patent number: 10881644Abstract: Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and an additive.Type: GrantFiled: February 28, 2018Date of Patent: January 5, 2021Assignee: Lutonix, Inc.Inventor: Lixiao Wang
-
Patent number: 10874607Abstract: Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.Type: GrantFiled: November 27, 2019Date of Patent: December 29, 2020Assignee: Skyline Biosciences LLCInventors: Hock S. Tan, Siew L. Chung
-
Patent number: 10864304Abstract: A material including a plurality of fatty acid chains cross-linked together and a silver fatty acid salt formed with the fatty acid chains within the material. Methods for forming a material are also included. The silver-containing materials can be utilized alone or in combination with a medical device for the release and local delivery of one or more anti-infective agents.Type: GrantFiled: May 19, 2014Date of Patent: December 15, 2020Assignee: ATRIUM MEDICAL CORPORATIONInventors: Keith M. Faucher, Hilda N. Rono, Anthony Richard Horton, Jocelyn Choroszy, Paul Martakos
-
Patent number: 10849859Abstract: The present disclosure is directed to random, acrylic co-polymers that are useful in transdermal applications. Methods of making and using the described co-polymers are also described.Type: GrantFiled: February 27, 2017Date of Patent: December 1, 2020Assignee: HENKEL IP & HOLDING GMBHInventors: Eric N. Silverberg, Young Taek Choi
-
Patent number: 10835487Abstract: According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.Type: GrantFiled: March 30, 2020Date of Patent: November 17, 2020Assignee: TherapeuticsMD, Inc.Inventors: Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner
-
Patent number: 10828389Abstract: The present invention relates to a haemostatic material comprising a carrier layer and a material for wound contact comprising at least one haemostat in particulate, granular, powder, flake or short fibrous form. Such a haemostatic material is useful, for example, in reducing or stopping bleeding of a physiological target site in a person or animal, and can also be used to stem bleeding during medical procedures.Type: GrantFiled: May 22, 2015Date of Patent: November 10, 2020Assignee: Medtrade Products LimitedInventors: Craig Julian Hardy, Andrew Darby, Guy Eason